Bay­er CEO talks next steps on in­fla­tion, sup­ply chain sta­bil­i­ty amid Q3 growth

Bay­er re­port­ed its Q3 earn­ings ear­ly Tues­day, and ex­ecs with the Ger­man gi­ant paint­ed a pic­ture of what’s next: con­cerns of more in­fla­tion.

CEO Wern­er Bau­mann told in­vestors and an­a­lysts on the phar­ma’s Q3 earn­ings call that the im­pact of in­fla­tion, al­ready some of the high­est in decades, was not quite ap­par­ent in Bay­er’s op­er­a­tions this year. And in 2023, to “ex­pect the full cost in­fla­tion ef­fects across the val­ue chain to ac­tu­al­ly ma­te­ri­al­ize.” Bau­mann con­tin­ued about Bay­er’s cost mit­i­ga­tion mea­sures, in­clud­ing how the com­pa­ny in­creased ef­fi­cien­cy mea­sures across the board and “ac­tive pric­ing man­age­ment” in crops and con­sumer health.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER